Alexza Pharma (ALXA) Volatility Elevated into FDA Meeting for Adasuve
Tweet
Share
E-mail
Get Alerts ALXA Hot Sheet
Join SI Premium – FREE
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) shares are showing some strong volatility Tuesday heading into its FDA meeting over Adasuve (Staccato loxapine), which is expected to happen on Friday, May 4th. The meeting was originally scheduled for February 4th.
Adasuve is a proposed treatment for acute agitation in patients with schizophrenia and bipolar disorder.
Last December, an FDA committee -- the Psychopharmacologic Drugs Advisory Committee -- voted 9-8-1 that Adasuve should be approved for use as a single dose in 24 hours when used with the FDA proposed Risk Evaluation and Mitigation Strategy.
Today, implied volatility is down slightly but remains nearly 320 percent above its historical average. The same movement was observed last December ahead of the FDA committee meeting.
Shares are about 1.9 percent better on the session. Alexza will also release its first-quarter 2012 earnings on May 10th, after the markets close.
Adasuve is a proposed treatment for acute agitation in patients with schizophrenia and bipolar disorder.
Last December, an FDA committee -- the Psychopharmacologic Drugs Advisory Committee -- voted 9-8-1 that Adasuve should be approved for use as a single dose in 24 hours when used with the FDA proposed Risk Evaluation and Mitigation Strategy.
Today, implied volatility is down slightly but remains nearly 320 percent above its historical average. The same movement was observed last December ahead of the FDA committee meeting.
Shares are about 1.9 percent better on the session. Alexza will also release its first-quarter 2012 earnings on May 10th, after the markets close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon to cut 3,000 jobs as it shifts stores to franchises
- DBV Technologies (DBVT) Misses Q2 EPS by 12c
- Molina Healthcare to join S&P MidCap 400, Construction Partners to join S&P SmallCap 600
Create E-mail Alert Related Categories
FDA, Momentum Movers, Options, Trader TalkRelated Entities
Options, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
